TY - JOUR
T1 - A multi-institutional retrospective study of carbon-ion radiotherapy for non-squamous cell malignant tumors of the nasopharynx
T2 - Subanalysis of Japan Carbon-Ion Radiation Oncology Study Group study 1402 HN
AU - Japan Carbon-Ion Radiation Oncology Study Group
AU - Abe, Takanori
AU - Ohno, Tatsuya
AU - Koto, Masashi
AU - Demizu, Yusuke
AU - Suefuji, Hiroaki
AU - Tsuji, Hiroshi
AU - Okimoto, Tomoaki
AU - Shioyama, Yoshiyuki
AU - Saitoh, Jun ichi
AU - Shirai, Katsuyuki
AU - Nemoto, Kenji
AU - Nakano, Takashi
AU - Kamada, Tadashi
AU - Katoh, Hiroyuki
N1 - Funding Information:
Japan Carbon‐ion Radiation Oncology Study Group is consisted of Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Sciences and Technology, Chiba, Japan (Masashi Koto: koto.masashi@qst.go.jp); Gunma University Heavy Ion Medical Center, Maebashi, Japan (Tatsuya Ohno: tohno@gunma-u.ac.jp); Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan (Tomoaki Okimoto: kiamoto935@ gmail.com); Ion Beam Therapy Center, SAGA HIMAT Foundation, Tosu, Japan (Yoshiyuki Shioyama: shioyama-yoshiyuki@saga-himat.jp); Kanagawa Cancer Center, Yokohama, Japan (Hiroyuki Katoh: hkatoh@kcch.jp)
Publisher Copyright:
© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2018/12
Y1 - 2018/12
N2 - Background: This multi-institutional retrospective study focused on the clinical outcome of carbon-ion radiotherapy (C-ion RT) for non-squamous cell malignant tumors of the nasopharynx. Methods: The Japan Carbon-ion Radiation Oncology Study Group collected and analyzed data for 43 patients with non-squamous cell malignant tumors of the nasopharynx treated with C-ion RT at four institutions in Japan. Results: Twenty-nine patients had adenoid cystic carcinomas, seven had malignant melanomas, three had adenocarcinomas, two had mucoepidermoid carcinomas, and two had other pathologies. Twenty-six of the 43 patients (61%) had T4 tumors. The most common dose-fractionation schedule was 64 Gy (relative biological effectiveness) in 16 fractions. The median follow-up period was 30 months. The 2-year local control (LC) and overall survival (OS) rates were 88% and 84%, respectively. For late toxicity, one patient developed grade 4 optic nerve disorder and two developed grade 5 pharyngeal hemorrhage. Actual incidence of grade 3 or higher late adverse events was 19%, and included cranial nerve dysfunction, jaw bone necrosis, central nervous system necrosis, and ear inflammation. Conclusions: C-ion RT provided good LC and OS rates with acceptable toxicity for treatment of non-squamous cell malignant tumors of the nasopharynx.
AB - Background: This multi-institutional retrospective study focused on the clinical outcome of carbon-ion radiotherapy (C-ion RT) for non-squamous cell malignant tumors of the nasopharynx. Methods: The Japan Carbon-ion Radiation Oncology Study Group collected and analyzed data for 43 patients with non-squamous cell malignant tumors of the nasopharynx treated with C-ion RT at four institutions in Japan. Results: Twenty-nine patients had adenoid cystic carcinomas, seven had malignant melanomas, three had adenocarcinomas, two had mucoepidermoid carcinomas, and two had other pathologies. Twenty-six of the 43 patients (61%) had T4 tumors. The most common dose-fractionation schedule was 64 Gy (relative biological effectiveness) in 16 fractions. The median follow-up period was 30 months. The 2-year local control (LC) and overall survival (OS) rates were 88% and 84%, respectively. For late toxicity, one patient developed grade 4 optic nerve disorder and two developed grade 5 pharyngeal hemorrhage. Actual incidence of grade 3 or higher late adverse events was 19%, and included cranial nerve dysfunction, jaw bone necrosis, central nervous system necrosis, and ear inflammation. Conclusions: C-ion RT provided good LC and OS rates with acceptable toxicity for treatment of non-squamous cell malignant tumors of the nasopharynx.
UR - http://www.scopus.com/inward/record.url?scp=85056772507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056772507&partnerID=8YFLogxK
U2 - 10.1002/cam4.1884
DO - 10.1002/cam4.1884
M3 - Article
C2 - 30449067
AN - SCOPUS:85056772507
SN - 2045-7634
VL - 7
SP - 6077
EP - 6083
JO - Cancer Medicine
JF - Cancer Medicine
IS - 12
ER -